Psoriasis treatment drug Benvimod cream approved by the National Drug Administration for listing

recently, with the continuous support of the National Science and Technology Major Special Project of "Significant(http://Creation", Benvimod emulsain (http://developed by Beijing Wenfeng TianjiPharmaceutical(http://Science and Technology LimitedCompany
(http:// has been approved by the State administration ofMedicines
(http://theAdministration for The Approval of the Priority Review and Approval ProcessAbout Benvimod CreamBenvimod Cream is the world's first class 1 new drug with complete independent intellectual property rights for local treatment of mild to moderate stability common psoriasis in adultsBenVimode cream, developed by Tianji Pharmaceuticals, a subsidiary of Crown Bio holdings, is a tyrosine protein kinase inhibitor that can be therapeutic by inhibiting the release of t-cell tyrosine protein kinase, interfering/blocking the release of cytokines and inflammatory media, T-cell migration, and activation of skin cellsThe availability of Benvimod creams will provide a new drug (http:// treatment for patients with mild to moderate stability in adults with common psoriasis patients 　　The results of the phase III clinical trial (http:// in China show that Benvimode has a higher cure rate compared with the first-line treatment drug "Capo triol" 　　Benvimod can be targeted at the local role of the skin, there is no treatment-related systemic adverse reactions, at the same time has a fast effect, long-lasting effect, low recurrence rate after discontinuation, high safety, accurate efficacy and other significant advantages The drug's availability will provide a new drug treatment for patients with mild to moderate stability common psoriasis patients in adults